Compare HROW & BRAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HROW | BRAI |
|---|---|---|
| Founded | 1998 | 2022 |
| Country | United States | Australia |
| Employees | N/A | 800 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 929.5M |
| IPO Year | 2008 | N/A |
| Metric | HROW | BRAI |
|---|---|---|
| Price | $28.43 | $3.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $65.00 | N/A |
| AVG Volume (30 Days) | ★ 550.4K | 35.7K |
| Earning Date | 11-09-2026 | 11-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.59 | N/A |
| Revenue Next Year | $53.17 | $30.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.96 | $3.93 |
| 52 Week High | $54.98 | $32.32 |
| Indicator | HROW | BRAI |
|---|---|---|
| Relative Strength Index (RSI) | 36.73 | 28.45 |
| Support Level | $26.96 | N/A |
| Resistance Level | $35.87 | $5.87 |
| Average True Range (ATR) | 1.41 | 0.49 |
| MACD | 0.19 | -0.08 |
| Stochastic Oscillator | 36.39 | 9.92 |
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Braiin Ltd is an Australian technology company leveraging proprietary intellectual property and patented artificial intelligence/machine learning (AI/ML) technologies to deliver actionable insights across the verticals: Agriculture, Property Technology, and Customer Experience as a Service (CXaaS). The company's platforms are designed to address inefficiencies and drive data-backed decision-making across traditionally analog sectors. It prominently focuses on the agriculture technology sector, where it has successfully deployed its AI-powered solutions across multiple implementations. It provides end-to-end solutions to improve farming productivity using IoTs, Wireless Connectivity, Robotics, Software and AI/ML.